This is a preview of subscription content, log in via an institution to check access.
Notes
This study was conducted and funded by Celltrion Healthcare.
Reference
Byun HG, et al. Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom Applied Health Economics and Health Policy : 12 Aug 2021. Available from: URL: https://doi.org/10.1007/s40258-021-00673-1
Rights and permissions
About this article
Cite this article
Subcutaneous infliximab may be cost saving for treating rheumatoid arthritis in the UK. PharmacoEcon Outcomes News 885, 22 (2021). https://doi.org/10.1007/s40274-021-07964-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-07964-9